Plasma kallistatin levels in patients with severe community-acquired pneumonia

Critical Care

Volumn 17, Issue 1, 2013, Pages

  Lin, Wei Chieh ^a   Lu, Shiou Ling ^b   Lin, Chiou Feng ^b   Chen, Chang Wen ^a   Chao, Lee ^c   Chao, Julie ^c   Lin, Yee Shin ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KALLISTATIN; PROTEIN C; STATIN (PROTEIN); TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CURB 65 SCORE; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MALE; MORTALITY; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEPTIC SHOCK; SURVIVOR;

EID: 84873468060     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12507     Document Type: Article

References (30)

1. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008, 133:610-617. 10.1378/chest.07-1456, 17989157.
2. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382. 10.1136/thorax.58.5.377, 1746657, 12728155.
3. Menendez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA, Martinez A, Esquinas C, Ramirez P, Torres A. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009, 64:587-591. 10.1136/thx.2008.105312, 19131448.
4. Chalmers JD, Singanayagam A, Scally C, Hill AT. Admission D-dimer can identify low-risk patients with community-acquired pneumonia. Ann Emerg Med 2009, 53:633-638. 10.1016/j.annemergmed.2008.12.022, 19201061.
5. Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008, 31:349-355. 10.1183/09031936.00054507, 17959641.
6. Bloos F, Marshall JC, Dellinger RP, Vincent JL, Gutierrez G, Rivers E, Balk RA, Laterre PF, Angus DC, Reinhart K, Brunkhorst FM. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care 2011, 15:R88. 10.1186/cc10087, 3219347, 21385367.
7. Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, Angus DC. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008, 52:48-58. e42, 10.1016/j.annemergmed.2008.01.003, 2775454, 18342993.
8. Lee JH, Kim J, Kim K, Jo YH, Rhee J, Kim TY, Na SH, Hwang SS. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J Crit Care 2011, 26:287-294. 10.1016/j.jcrc.2010.10.007, 21129911.
9. Coelho LM, Salluh JI, Soares M, Bozza FA, Verdeal JC, Castro-Faria-Neto HC, Lapa ESJR, Bozza PT, Povoa P. Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care 2012, 16:R53. 10.1186/cc11291, 22449513.
10. Chao J, Schmaier A, Chen LM, Yang Z, Chao L. Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med 1996, 127:612-620. 10.1016/S0022-2143(96)90152-3, 8648266.
11. Zhou GX, Chao L, Chao J. Kallistatin: a novel human tissue kallikrein inhibitor: purification, characterization, and reactive center sequence. J Biol Chem 1992, 267:25873-25880.
12. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002, 100:3245-3252. 10.1182/blood-2002-01-0185, 12384424.
13. Chao J, Yin H, Yao YY, Shen B, Smith RS, Chao L. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 2006, 17:1201-1213. 10.1089/hum.2006.17.1201, 17081080.
14. Shen B, Hagiwara M, Yao YY, Chao L, Chao J. Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension 2008, 51:1358-1365. 10.1161/HYPERTENSIONAHA.107.108514, 18391098.
15. Chen LM, Chao L, Chao J. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci 1997, 60:1431-1435. 10.1016/S0024-3205(97)00094-5, 9126863.
16. Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L, Chao J. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 2005, 52:1319-1324. 10.1002/art.20991, 15818689.
17. Hsieh JL, Shen PC, Shiau AL, Jou IM, Lee CH, Teo ML, Wang CR, Chao J, Chao L, Wu CL. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther 2009, 20:147-158. 10.1089/hum.2008.096, 20377366.
18. Gao L, Yin HS, Smith RJ, Chao L, Chao J. Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest 2008, 88:1157-1166. 10.1038/labinvest.2008.85, 18762777.
19. Diao Y, Zhao XF, Lin JS, Wang QZ, Xu RA. Protection of the liver against CCl4-induced injury by intramuscular electrotransfer of a kallistatin-encoding plasmid. World J Gastroenterol 2011, 17:111-117. 10.3748/wjg.v17.i1.111, 3016670, 21218091.
20. Wolf WC, Harley RA, Sluce D, Chao L, Chao J. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem 1999, 47:221-228. 10.1177/002215549904700210, 9889257.
21. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754. American Thoracic Society.
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
23. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710. 10.1007/BF01709751, 8844239.
24. Milbrandt EB, Reade MC, Lee M, Shook SL, Angus DC, Kong L, Carter M, Yealy DM, Kellum JA. Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med 2009, 15:438-445. 2743205, 19753144.
25. Agapakis DI, Tsantilas D, Psarris P, Massa EV, Kotsaftis P, Tziomalos K, Hatzitolios AI. Coagulation and inflammation biomarkers may help predict the severity of community-acquired pneumonia. Respirology 2010, 15:796-803. 10.1111/j.1440-1843.2010.01773.x, 20497384.
26. Oehmcke S, Herwald H. Contact system activation in severe infectious diseases. J Mol Med (Berl) 2010, 88:121-126.
27. Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007, 62:253-259. 10.1136/thx.2006.067371, 2117168, 16928720.
28. Ramirez P, Ferrer M, Marti V, Reyes S, Martinez R, Menendez R, Ewig S, Torres A. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011, 39:2211-2217. 10.1097/CCM.0b013e3182257445, 21705887.
29. Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 2005, 33:341-348. 10.1097/01.CCM.0000153520.31562.48, 15699837.
30. Blackberg M, Berling R, Ohlsson K. Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin. Pancreas 1999, 19:325-334. 10.1097/00006676-199911000-00002, 10547191.